Cancer Research Meeting Calendar Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jost, M.
Right arrow Articles by Noël, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jost, M.
Right arrow Articles by Noël, A.
[Cancer Research 66, 5234-5241, May 15, 2006]
© 2006 American Association for Cancer Research

Cell, Tumor, and Stem Cell Biology

Earlier Onset of Tumoral Angiogenesis in Matrix Metalloproteinase-19–Deficient Mice

Maud Jost1, Alicia R. Folgueras3, Françoise Frérart1, Alberto M. Pendas3,4, Silvia Blacher1, Xavier Houard1, Sarah Berndt1, Carine Munaut1, Didier Cataldo1, Jesus Alvarez3, Laurence Melen-Lamalle1, Jean-Michel Foidart1,2, Carlos López-Otín3 and Agnès Noël1

1 Laboratory of Tumor and Developmental Biology, Center for Experimental Cancer Research, Center for Biomedical Integrative Genoproteomics, University of Liège, Tour de Pathologie (B23); 2 Department of Gynecology, Centre Hospitalier Universitaire, Liège, Belgium; 3 Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain; and 4 Centro Investigacion Cancer, Salamanca, Spain

Requests for reprints: Agnès Noël, Laboratory of Tumor and Developmental Biology, University of Liège, Tour de Pathologie (B23), Sart-Tilman, B-4000 Liège, Belgium. Phone: 32-4-366-25-69; Fax: 32-4-366-29-36; E-mail: agnes.noel{at}ulg.ac.be.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Among matrix metalloproteinases (MMP), MMP-19 displays unique structural features and tissue distribution. In contrast to most MMPs, MMP-19 is expressed in normal human epidermis and down-regulated during malignant transformation and dedifferentiation. The contribution of MMP-19 during tumor angiogenesis is presently unknown. In an attempt to give new insights into MMP-19 in vivo functions, angiogenic response of mutant mice lacking MMP-19 was analyzed after transplantation of murine malignant PDVA keratinocytes and after injection of Matrigel supplemented with basic fibroblast growth factor. In situ hybridization and immunohistochemical analysis revealed that MMP-19 is produced by host mesenchymal cells but not by endothelial capillary cells or CD11b-positive inflammatory cells. Based on a new computer-assisted method of quantification, we provide evidence that host MMP-19 deficiency was associated with an increased early angiogenic response. In addition, increased tumor invasion was observed in MMP-19–/– mice. We conclude that, in contrast to most MMPs that promote tumor progression, MMP-19 is a negative regulator of early steps of tumor angiogenesis and invasion. These data highlight the requirement to understand the individual functions of each MMP to improve anticancer strategies. (Cancer Res 2006; 66(10): 5234-41)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Matrix metalloproteinases (MMP) are a family of structurally related zinc-dependent neutral endopeptidases that play major roles in tissue remodeling occurring in a variety of physiologic processes, such as embryonic development, angiogenesis, and wound healing (1, 2). They are main effectors of pathologic extracellular matrix destruction in many diseases, such as arthritis, atherosclerosis, age-related macular degeneration, tumor invasion, and metastasis (3–7). MMPs contribute to the fine tuning of diverse biological processes through limited proteolysis of specific targets, including not only matrix components, but also growth factors, chemokines/cytokines, and cell surface receptors (8–11). More than 20 different human MMPs have been identified (12) and classified into different subfamilies according to their primary structure, domain organization, cellular localization, and substrate specificity (11, 13, 14). Produced as latent forms, they are either secreted in the extracellular medium or associated to the cell membrane (membrane-type MMPs; refs. 7, 11, 14).

Among MMPs, MMP-19 displays unique structural features and tissue distribution. Human MMP-19 cDNA was initially cloned from liver and mammary gland and was also identified as an autoantigen in inflamed rheumatoid synovium (15, 16). MMP-19 presents the typical domain organization of soluble MMPs, including a signal sequence, a propeptide maintaining enzyme latency, a catalytic domain with the typical zinc-binding motif, a linker region, and a COOH-terminal fragment with sequence similarity to hemopexin (15). However, MMP-19 displays several structural features distinctive of the diverse MMP subfamilies, including (a) an unique insertion of glutamic acid residues within the linker region, (b) an unusual latency motif in propeptide domain, (c) an additional cysteine residue in catalytic region, and (d) a COOH-terminal extension lacking sequence similarity to equivalent regions in other human MMPs (15, 17, 18). The catalytic domain of MMP-19 is capable of degrading components of basement membrane (laminin, type IV collagen, nidogen), connective tissue (fibronectin, type I gelatin), and cartilage (cartilage oligomeric matrix protein and aggrecan), but does not degrade triple-helical type I collagen (19, 20). In contrast to most other MMPs, MMP-19 is expressed in human mammary or skin epithelial cells under normal quiescent conditions and down-regulated in invasive carcinomas (21–23).

Evidence for MMP-19 involvement in tissue remodeling events, such as those occurring during adipogenesis and tumor progression, have been provided by the recent generation of MMP-19-deficient mice (24). Although lack of MMP-19 did not affect mice viability, fertility, and development, it led to a diet-induced obesity and a decreased susceptibility to skin tumors induced by chemical carcinogens. A role of MMP-19 during angiogenesis is suggested by its expression in endothelial cells of synovial capillaries following injury and inflammation (3, 25). However, the ex vivo sprouting of endothelial cells from aortic rings was not affected by MMP-19 deficiency (24). Therefore, the contribution of MMP-19 during angiogenic processes remains controversial. To give new insights into MMP-19 functions in vivo, the angiogenic response of mutant mice lacking MMP-19 was analyzed after transplantation of malignant murine PDVA keratinocytes and after injection of Matrigel supplemented with basic fibroblast growth factor (bFGF). In contrast to other single or double MMP-deficient mice studied until now, MMP-19-deficient mice exhibited an early onset of angiogenesis and tumor invasion.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
MMP-19-null mice. Mice genetically deficient in MMP-19 (MMP-19–/–) were generated by replacing a portion of 1 kb of the promoter and exons 1 and 2 of the gene with a phosphoglycerate kinase-neomycin fusion gene and by homologous recombination (24). Homozygous MMP-19 (MMP-19–/–) mice and their corresponding wild type (WT; MMP-19+/+) were littermates deriving from interbreeding of heterozygotes with a mixed background of C57Bl6/129Ola. When applying the transplantation chamber assay to mice with different genetic background, we previously showed that the extent of tumor invasion and vascularization was similar in all WT mice, independently to the number of backcrosses in C57Bl6 mice (26). Mice experimentation was done in accordance to guidelines of the University of Liège regarding the care and use of laboratory animals.

Transplantation assay in mice. PDVA cells were generated by in vitro carcinogen treatment (dimethylarsinic acid) of cultured keratinocytes issued from B10LP mice (27). PDVA cells were grown in modified Eagle's MEM containing a 4-fold concentration of amino acids and vitamins (Life Technologies Laboratories, Grant Island, NY), 10% FCS (Life Technologies), and antibiotics in a humidified incubator at 37°C, 5% CO2. Cells (2 x 105) were seeded on a collagen gel (4 mg/mL of type I collagen isolated from rat tail tendons) inserted in Teflon rings (Renner GmbH, Darmstadt, Germany). After 24 hours of culture, cell-coated collagen gels were covered with a silicone transplantation chamber (Renner) and implanted in toto onto dorsal muscle fascia of 6 to 8 weeks old mice according to the procedure previously described (28, 29). At different time points, tumor transplants were resected, embedded in Tissue Tek (Miles Laboratories, Inc., Naperville, IL), and frozen in liquid nitrogen for cryostat sectioning. Two hours before sacrifice, mice were i.p. injected with 200 µL BrdUrd/BrdC (65 µmol/L, Acros Organics, Geel, Belgium). Each experimental group contained at least six animals. Tumor angiogenesis and invasion in MMP-19–/– and WT mice were evaluated in three independent sets of experiment.

Histologic analysis. Cryostat sections were fixed in acetone at –20°C and in 80% methanol at 4°C. For immunofluorescence labeling, the following antibodies were used: anti-type IV collagen antibody (rabbit polyclonal antibody; diluted 1/100), antikeratin antibody (polyclonal guinea pig antibody; diluted 1/20, Sigma-Aldrich, St. Louis, MO), anti-BrdUrd-FITC (monoclonal mouse, diluted 1/3.5, Becton Dickinson, San Diego, CA), anti-hinge region of MMP-19 (rabbit anti-human, diluted 1/20, Sigma-Aldrich; rabbit anti-human, diluted 1/500, Abcam, Cambridge, MA), anti-MMP-19 prodomain (rabbit anti-human, diluted 1/500, Abcam), anti-CD11b/tetramethyl-rhodamine isothiocyanate (TRITC; rat anti-mouse, diluted 1/50, PharMingen, San Diego, CA), anti-{alpha}-smooth muscle actin ({alpha}-SMA)/FITC (monoclonal mouse antibody, diluted 1/200, Sigma-Aldrich). When double-immunofluorescence labelings were done, after an incubation for 1 hour with primary antibodies, sections were washed with PBS and then incubated for 30 minutes with FITC- or TRITC-conjugated appropriate secondary antibodies: swine anti-rabbit (diluted 1/40, DAKO, Glostrup, Denmark), mouse anti-guinea pig (diluted 1/40, Sigma-Aldrich), or goat anti-rat (diluted 1/100, Molecular Probes, Carlsbad, CA). After three washes in PBS, coverslips were mounted with Aqua Polymount (Polysciences, Warrington, FL) and specific labeling was observed using an inverted microscope equipped with epifluorescence optics. Sections were counterstained in blue with bisbenzimide. At all times after grafting, collagen type IV labelings were codistributed with endothelial cells recognized by the anti-mouse PECAM immunostaining (data not shown).

Apoptosis was studied by terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling (TUNEL). Cryostat sections fixed in 4% paraformaldehyde for 20 minutes and in methanol for 5 minutes were stained for apoptosis following instructions of the manufacturer (Roche Diagnostics, Mannheim, Germany).

For quantitative measurement of proliferating cells, automatic computer-assisted image analysis was done on images obtained after bisbenzimide staining and immunolabeling of BrdUrd-positive cells. The ratio between the surface of bisbenzimide staining and the surface of specific immunostaining was measured by using a software Aphelion 3.2 from Adsis (Herouville Saint Clair, France).

In situ hybridization. Either sense or antisense 35S-UTP-labeled RNA probes were synthesized from linearized cDNA fragment (1,600 bp) of mouse MMP-19 gene cloned into EcoRV site of pcDNA3. Cryostat sections were hybridized with 35S-labeled MMP-19 riboprobes and then exposed to photographic emulsion at 4°C for 6 days. Sections were developed, fixed, cleared, and counterstained with 0.02% toluidine blue. Bright field and dark field images were captured with a SPOT digital camera.

Scoring of tumor invasion and vascularization. For semiquantitative analysis of tumor vascularization, the following scoring was used: +, vessels below the collagen gel or infiltrating the collagen gel without reaching the malignant epithelial layer; ++, blood vessels in close apposition to the epithelial layer; and +++, blood vessels intermingled with invasive epithelial tumor sprouts (29).

Morphometric measurements of tumor cell invasion (average distance of invasion) and tumor vascularization (endothelial cell migration) were done by using a computer-assisted image analysis system (Olympus Micro Image version 3.0 for Windows 95/NT, Olympus Optical Co., Europe GmBH, Tokyo, Japan; ref. 30). Angiogenesis was quantified by measuring the distance (d) separating tumor cells from the front of migrating blood vessels. Therefore, the distance d is inversely related to the degree of endothelial cell migration. At least five measurements of distance (d) were done in the central part of each tumor and the mean values are reported.

Quantitative measurement of tumor invasion and angiogenesis by computer-assisted image processing. For quantitative measurements, automatic computer-assisted image analysis was done on images obtained after double immunostainings of keratinocytes (in green) and vessels (in red). The software Aphelion 3.2 from Adsis was used on a personal computer. Images were first digitized in 760 x 570 pixels with 256 Gray levels. Tumor and vessel images were processed separately. For tumor images, histogram equalization was first done to optimize the contrast. Then, tumor images were binarized/segmented automatically using the entropy of the histogram of the gray level intensities (31). For vessel images, vessels were binarized/segmented using an automatic threshold transformation that maximizes the global average contrast of edges (32). The upper boundary of the tumor was then automatically detected using a hit or miss transformation with an appropriate neighborhood configuration. A grid was constructed with the successive dilations (n = 1, 2, 3....) of this upper boundary, with a vertical line as structuring element. Tumor and vessel densities were determined on each interval of the grid, and the results drawn in function of the distance to the upper limit of the tumor. The largest distance of tumor invasion gives the thickness of the tumor. Quantification was done on each mouse in all independent assays. To compare the different distributions, the ANOVA was done and results were considered significantly different when the P value was <0.05.

Matrigel plug assay. A total of 0.5 mL Matrigel (10 mg/mL) mixed with 250 ng bFGF (R&D Systems, Minneapolis, MN) and 20 units heparin (Leo Pharma, Ballerup, Denmark; ref. 33) was s.c. injected in the abdominal midline region of 8-week-old MMP-19 null and WT mice. After 7 days, animals were euthanized and Matrigel implants were harvested, frozen on dry ice, and lyophilized overnight. Dry plugs were weighed and suspended in 0.4 mL of 0.1% saponin (Calbiochem, La Jolla, CA) for 1 hour at 4°C, disrupted by vigorous pipetting and centrifuged at 15,000 x g for 15 minutes, at 4°C to remove particulates. Concentration of hemoglobin in the supernatant was determined after dilution in Drapkin's solution by measuring the absorbance at 560 nm (Drabkin reagent kit 525, Sigma, St. Louis, MO). A standard curve was done by using purified hemoglobin (Sigma). The angiogenic index corresponds to µg of hemoglobin per mg of Matrigel.

Statistical analysis. All experimental data are reported as mean ± SE, and statistical analysis was done by {chi}2 test or Mann-Whitney test. P < 0.05 was considered as significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Lack of MMP-19 increased the onset of skin tumor vascularization. Malignant PDVA keratinocytes cultured on a collagen gel were implanted onto the dorsal muscle fascia of MMP-19–/– and MMP-19+/+ mice. To compare evolution of tumor invasion and vascularization in these genotypes, transplants were resected after 14 and 21 days and angiogenesis was visualized after staining for collagen type IV to delineate capillary basement membranes (Fig. 1 ). Tumor grafting led to a remodeling of collagen matrix and a progressive infiltration by host-derived cells, including endothelial cells and inflammatory cells. Tumor vascularization was semiquantitatively scored according to the progressive migration of blood vessels toward tumor cells (Fig. 1). At day 14, in MMP-19+/+ mice, blood vessels remained below the collagen gel or started to infiltrate it and all samples were scored + (Fig. 1A). Tumor vascularization in MMP-19–/– mice was increased because 63% and 37% of transplants were scored + and ++, respectively (P < 0.05, {chi}2 test; Fig. 1B). At that time, in both genotypes, tumor layer appeared as an irregular stratified epithelium on top of the collagen gel (Fig. 1A).


Figure 1
View larger version (32K):
[in this window]
[in a new window]
  		Figure 1. A, histologic analysis of tumor transplants. Immunofluorescence labeling of malignant keratinocytes and vessels in tumors transplanted into MMP-19+/+ or MMP-19–/– mice observed after 14 days (D14) or 21 days (D21). Malignant cells (green, antikeratin antibody) and vessels (red, anticollagen type IV antibody) are visualized. Dotted line, front of endothelial cell migration. Scores and morphometric variable (d) used to quantify tumor invasion and angiogenesis are indicated (original magnification, x200). B to C, semiquantitative evaluation of tumor vascularization in MMP-19+/+ (black columns) or MMP-19–/– mice (white columns). Tumors were scored as shown in A and in Materials and Methods. n, number of animals per group. D, quantification of tumor vascularization in tumors transplanted for 14 days in MMP-19+/+ (black columns) or MMP-19–/– (white columns) mice. d, distance separating tumor cell layer from the front of migrating blood vessels as defined in A (see Materials and Methods; **, P ≤ 0.01, Mann-Whitney test; n = 8). k, malignant keratinocytes; c, collagen gel; h, host tissue.

 
Vascularization of tumor transplants at day 14 was first quantified by measuring the distance (d) separating the bottom of tumor layer from the front of migrating blood vessels (Fig. 1D). This variable is inversely related to the degree of endothelial cell migration. Compared with MMP-19+/+ mice, vessels migrated over a higher distance in MMP-19-deficient mice (Fig. 1D). Indeed, the distance separating endothelial cells to malignant keratinocytes was 2.5-fold reduced in MMP-19 null mice than in their corresponding WT littermates (P = 0.0062, Mann-Whitney test; Fig. 1D).

The observed increased blood vessel migration in MMP-19-null mice prompted us to set up a more objective quantitative method to investigate the spatial distribution of blood vessels in the remodeled matrix. With this aim, an original method based on computer-assisted image analysis was developed (Fig. 2A ). The density of vessels picked already at a distance of around 0.25 mm from the upper boundary of tumor layer in MMP-19–/– mice (Fig. 2B). In sharp contrast, the maximal density of endothelial cells was observed at a distance of around 0.75 mm in MMP-19+/+ mice. A computer-assisted method of image analysis was also set up to quantify tumor cell invasion (Fig. 2A). At day 14 time point, no invasion was observed (Fig. 2C). This was expected because in the transplantation chamber assay, infiltration of vessels through the collagen gel toward tumor cells always precedes recognizable tumor cell invasion (34). Therefore, at early time point, MMP-19-deficient mice exhibited an acceleration of blood vessel infiltration in the remodeled matrix.


Figure 2
View larger version (32K):
[in this window]
[in a new window]
  		Figure 2. Quantification of tumor vascularization and invasion in tumor transplants based on computer-assisted image analysis. A, image processing of a typical transplant section. Malignant keratinocytes (green) and vessels (red; original image) were immunostained according to the procedure described in Materials and Methods. Images are binarized with extraction of vessels (Vascularization) or of tumor cells (Invasion). Tumor vascularization and tumor invasion were determined by using a grid obtained by successive dilation of the tumor upper border. B to D, determination of vessel density (normalized density of endothelial cells; B) and tumor cell density (normalized density of tumor cells; C and D) as a function of the distance to the upper boundary of tumor layer. The maximal distance of tumor cell invasion corresponds to tumor thickness (D). Malignant keratinocytes were transplanted into MMP-19+/+ (WT) and MMP-19–/– (KO) mice for 14 or 21 days.

 
Lack of MMP-19 increased tumor invasion. At day 21, once blood vessels have reached tumor cell layers, malignant keratinocytes formed tumor sprouts that invaded downward the remodeled host tissue and were intermingled with closely apposed new vessels (Fig. 1A). Such vascularization pattern scored +++ was observed in ~60% (10 of 17) of MMP-19–/– mice and only 22% (4 of 18) of MMP-19+/+ mice (P = 0.027, {chi}2 test; Fig. 1C).

At this time point, the distance (d) separating tumor layer from the front of recruited blood vessels (Fig. 1) cannot be measured because in >70% of tumor transplants, vessels have reached the tumor layer (tumors scored ++ or +++). Therefore, for quantitative assessment, our original method of image analysis (Fig. 2) was applied to determine the malignant keratinocyte density as a function of the distance to the top of tumor transplant (Fig. 2D). In WT mice, keratinocyte density decreased abruptly with the distance to the top of tumor layer (Fig. 2D). Only few keratinocytes were observed at a distance >0.5 mm from the top of tumor layer. In sharp contrast, in MMP-19 null mice, tumor cell density decreased more slowly and numerous malignant keratinocytes migrated over a distance of 0.5 mm. The maximal distance of keratinocyte migration was 1.2 and 1.8 mm in MMP-19+/+ and MMP-19–/– mice, respectively (Fig. 2D). Therefore, a significant increase of tumor invasion was observed in the absence of host MMP-19.

This tumor-promoting effect observed in absence of MMP-19 was not related to a modification of tumor cell proliferation rate as assessed by BrdUrd incorporation. Indeed, quantitative assessment done by computer-assisted image analysis revealed that the percentage of proliferating cells was similar in both genotypes 14 and 21 days after tumor transplantation (Fig. 3 ). Furthermore, TUNEL stainings for apoptotic cells indicated that the extent of apoptosis was identical and always low in cancer cell layers as well as in stromal strands of transplants resected from WT mice and MMP-19–/– mice (data not shown).


Figure 3
View larger version (10K):
[in this window]
[in a new window]
  		Figure 3. BrdUrd immunostaining of tumor transplants. Malignant keratinocytes were transplanted for 14 days (A) or 21 days (B) into MMP-19+/+ (black columns) or MMP-19–/– (white columns) mice. Before sacrifice, mice were injected with BrdUrd and immunostaining was done on tumor sections. The percentage of positive cells was determined by a computer-assisted method described in Materials and Methods.

 
MMP-19 is produced by host stromal cells. As a first step in determining the cellular source of MMP-19, in situ hybridization was done on tumors transplanted into MMP-19-proficient and MMP-19-deficient mice. Hybridization signals for MMP-19 mRNAs were found in the stroma of WT mice (Fig. 4A ) but not in that of knockout (KO) mice (Fig. 4C). No positive signal was detected after treatment with sense riboprobe used as negative controls (Fig. 4B). Immunohistochemical staining of tumor transplants confirmed the stromal production of MMP-19 (Fig. 5A ). This protease was produced by mesenchymal cells (Fig. 5A) but not by inflammatory cells positive for CD11b staining (Fig. 5C). Interestingly, MMP-19 was not associated with capillaries newly formed in the remodeled collagen matrix (data not shown). In contrast, MMP-19 staining was detected in large vascular structures present deeply in the host tissue, below tumor transplants (Fig. 5B). These vessels were positive for {alpha}-SMA and correspond to quiescent mature vessels.


Figure 4
View larger version (36K):
[in this window]
[in a new window]
  		Figure 4. In situ hybridization of tumor transplants. Sections of malignant keratinocytes transplanted into MMP-19+/+ (A and B) and MMP-19–/– (C) mice for 21 days were hybridized with 35S-labeled antisense MMP-19 riboprobe (A and C) or sense MMP-19 riboprobe (B) used as negative control. Bright-field (left) and dark-field (right) images were both captured. Stromal cells in host tissue (h), but not malignant keratinocytes (k), were positively stained for MMP-19 mRNAs (original magnification, x100).

 

Figure 5
View larger version (35K):
[in this window]
[in a new window]
  		Figure 5. Immunostaining of tumors transplanted into WT mice. Sections are counterstained with bisbenzimide (blue staining). Host stromal cells are positive for MMP-19 immunostaining (green; original magnification, x200; A). Double immunostainings reveal that MMP-19 (red) is not present in newly formed vessels in collagen matrix but is associated to vascular structures stained with {alpha}-SMA antibody (green) and localized deeply in host tissue (original magnification, x400; B). MMP-19 (green) does not colocalize with CD11b-positive inflammatory cells (red; original magnification, x400; C). Higher magnification is shown in inset (C).

 
Lack of MMP-19 increased angiogenesis in Matrigel plug assay. To further investigate the effect of MMP-19 deficiency on angiogenesis in vivo and to determine whether the angiogenic response was dependent on the matrix encountered by endothelial cells during their migration, the Matrigel plug assay was applied to mutant mice. Matrigel supplemented with bFGF was s.c. injected into the abdomen of WT and mutant mice (n = 8) and harvested after 7 days. Quantitative analysis of angiogenesis was done by measuring hemoglobin content in implants giving quantitative information on functional vessels. In accordance to results obtained in transplantation chamber assay, the angiogenic response in MMP-19-deficient mice was 6-fold increased compared with that detected in WT mice (Fig. 6 ; P < 0.05) and was therefore independent on the type of matrix used (type I collagen versus a reconstituted basement membrane).


Figure 6
View larger version (8K):
[in this window]
[in a new window]
  		Figure 6. Increased vascularization in Matrigel plug containing bFGF and implanted in MMP-19–/– mice. Functional vascularization was quantified by measuring hemoglobin concentration in Matrigel plug implanted into MMP-19+/+ and MMP-19–/– mice. *, P ≤ 0.05.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The analysis of cancer susceptibility in individual MMP-null mice is of growing interest after the failure of synthetic MMP inhibitors in clinical trials and the finding of multiple and even opposite roles of MMPs in tumor progression. We describe here that in contrast to most MMP deficiencies described up to now in mice, the angiogenic response was accelerated and tumor invasion was increased in MMP-19-deficient mice. This was evidenced by (a) an accelerated vascularization and a higher degree of tumor invasion after malignant keratinocyte transplantation and (b) an increased vascularization in bFGF-treated Matrigel implants in MMP-19–/– mice.

The time course of malignant growth begins with an early onset of stromal activation and infiltration of inflammatory cells and endothelial cells. These key events can be mimicked in the transplantation system used here, which is a highly sensitive tool to inspect kinetics of early steps of host stromal response to tumor signals (34, 35). By applying this system to MMP-19–/– mice, it seems that the angiogenic response was affected by lack of host MMP-19. Surprisingly, endothelial cell recruitment was significantly increased 14 days after transplantation, leading to an acceleration of tumor vascularization. Consequently, tumor invasion was increased in MMP-19-deficient mice 21 days after tumor transplantation. These findings indicate that MMP-19 is a negative regulator of early steps of cancer angiogenesis and invasion.

By in situ hybridization and immunohistochemical analysis, we show that mesenchymal cells produce MMP-19, whereas CD11b-positive inflammatory cells and malignant keratinocytes do not express it. Accordingly, MMP-19 mRNA expression and pro-MMP-19 production by human fibroblasts have been detected in vivo in dermal wounds and in cultures of fibroblasts (36). In our model, MMP-19 is not produced by sprouting endothelial cells of neo-formed capillaries. This observation fits with our previous observation that MMP-19 is not required for ex vivo endothelial cell migration in a collagen gel in the aortic ring assay (24). According to the report of Kolb et al. (25), MMP-19 is associated with {alpha}-SMA-positive large vessels deeply embedded in the host tissue.

Taking into account its in vitro substrates (laminin-1, laminin-5, type IV collagen, fibronectin, tenascin-C, or nidogen), MMP-19 might play a key role in matrix degradation and tissue remodeling (19, 20, 37). A recent in vitro study suggests that through its capacity to cleave nidogen, MMP-19 could control formation of capillary structures on Matrigel by cultured endothelial cells (38). However, the ex vivo endothelial cell sprouting from mouse aortic rings in a three-dimensional matrix was not affected by MMP-19 deficiency (24). Therefore, the accelerated angiogenic response observed in vivo in the transplantation system could not be ascribed to a modified ability of endothelial cells to migrate or differentiate into capillary-like structures in a pure collagen matrix in the absence of MMP-19. Interestingly, the accelerated recruitment of endothelial cells in vivo was observed both in transplantation system using type I collagen and in Matrigel plug assay, suggesting that this effect of MMP-19 on angiogenesis was not dependent on the matrix used.

The identification of novel non-matrix substrates for MMPs has extended MMP functions beyond their classic role in extracellular matrix disruption (4, 11). The recent finding that MMP-19 cleaves in vitro insulin-like growth factor binding protein-3 (39) suggests that it could control the activity of insulin-like growth factors and thereby regulate cancer cell growth. However, in our system, tumor cell proliferation was not affected by MMP-19 deficiency. Similarly, tumor cell apoptosis was not modulated by the absence of host MMP-19. It is worth noting that proteolytic processing of some bioactive molecules, such as growth factors and/or cytokines/chemokines, could also indirectly contribute to microenvironment modifications promoting or inhibiting endothelial cell recruitment during angiogenesis onset. The assumption that MMPs are in general proangiogenic has been challenged by the finding that some of them could suppress neovascularization by generating angiogenic inhibitors (40). In this context, MMP-19 could exert its antiangiogenic effect through inactivation of angiogenic/chemotactic factors or production/maturation of angiogenic inhibitors. In addition, MMP-19 production in large quiescent host vessels present below tumor transplants, but not in growing capillaries, suggests a yet unknown functional role of this protease in maintenance of blood vessel stability. Its absence could destabilize endothelial cell–mural cell interactions, thereby initiating active sprouting events and endothelial cell migration. This hypothesis could explain the transient effect of MMP-19 deficiency at angiogenesis onset.

The present results do not negate the possibility that MMP-19 might have dual functions during cancer progression. In a model of methylcholanthrene-induced chemical carcinogenesis, we previously showed that MMP-19–/– mice develop less fibrosarcomas and with a longer latency period than WT littermates (24). These apparently paradoxical results may reflect different roles of MMP-19 in the evolution of various cancer types (carcinoma versus fibrosarcoma), as well as throughout different steps of cancer progression. The down-regulation and disappearance of MMP-19 production observed during neoplastic progression in breast and skin carcinomas (21–23) are consistent with our data demonstrating a control of early steps of skin carcinoma evolution by MMP-19. Altogether, these data based on clinical and experimental studies suggest that MMP-19 negatively regulates early stages of tumor cell invasion, but cancer cells could become less sensitive to MMP-19 activity once tumor develops. Temporal differences in effect of proteases on tumor growth and conversion to aggressive tumors have also been reported for MMP-9 (41) and MMP-11 (42).

By applying the same transplantation chamber assay into different single or double MMP-deficient mice (43), we previously reported that tumor invasion and angiogenesis were both impaired by the combined deficiency in MMP-2 and MMP-9 demonstrating that concomitant production of gelatinases is required for tumor invasion and vascularization. Therefore, although MMP-2 and MMP-9 are viewed as positive regulators of tumor angiogenesis (4, 41, 44, 45), MMP-19 could function in an opposite manner, slowing down the angiogenic process. These unexpected data are in accordance with the emerging antitumor properties of some MMPs. In this context, skin tumor susceptibility was increased in mice deficient for MMP-8 (46) or MMP-3 (47). Furthermore, our results support the view that MMPs act as sophisticated modulators rather than simple inducers or suppressors and highlight the functional complexity of MMP family during cancer progression. Some MMPs appear to have dual role in cancer progression by promoting angiogenesis and generating angiogenesis inhibitors (6). For instance, although MMP-7 and MMP-9 are both able to generate angiostatin (40), MMP-7 facilitates tumor progression in mouse models (48) and MMP-9 promotes tumor angiogenesis (41, 43–45). Increased expression of some MMPs may both confer increased tumor cell invasiveness and, paradoxically, lead to production of molecules that limit tumor growth. Altogether, these data point out the need to determine both spatial and temporal significance of individual MMP during cancer progression to design more rational MMP inhibitors.


   Acknowledgments
 
Grant support: Communauté Française de Belgique (Actions de Recherches Concertées), the European Union (FP5 and FP6), the Fonds National de la Recherche Scientifique (Belgium), the Fédération Belge Contre le Cancer, the Centre Anticancéreux près l'Université de Liège, the FB Assurances, the Fondation Léon Frédéricq (University of Liège), the Direction Générale des Technologies, de la Recherche et de l'Energie from the "Région Wallonne," the Interuniversity Attraction Poles Programme-Belgian Science Policy (Brussels, Belgium), the Comision Interministerial de Ciencia y Tecnologia (C. López-Otín), and Fonds National de la Recherche Scientifique-Télévie (M. Jost and S. Berndt).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank I. Dasoul, P. Gavitelli, F. Olivier, and G. Roland for their excellent technical assistance.


   Footnotes
 
Note: D. Cataldo is a scientific research worker from the Fonds National de la Recherche Scientifique (Belgium).

Received 12/ 2/05. Revised 2/16/06. Accepted 3/14/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999;274:21491–4.[Free Full Text]
  2. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000;14:2123–33.[Free Full Text]
  3. Konttinen YT, Ainola M, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691–7.[Abstract/Free Full Text]
  4. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004;48:411–24.[CrossRef][Medline]
  5. Noel A, Maillard C, Rocks N, et al. Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol 2004;57:577–84.[Abstract/Free Full Text]
  6. Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005;115:849–60.[CrossRef][Medline]
  7. Sounni NE, Noel A. Membrane type-matrix metalloproteinases and tumor progression. Biochimie 2005;87:329–42.[Medline]
  8. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463–516.[CrossRef][Medline]
  9. McQuibban GA, Gong JH, Tam EM, McCulloch CAG, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000;289:1202–6.[Abstract/Free Full Text]
  10. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001;276:43503–8.[Abstract/Free Full Text]
  11. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161–74.[Medline]
  12. Puente XS, Lopez-Otin C. A genomic analysis of rat proteases and protease inhibitors. Genome Res 2004;14:609–22.[Abstract/Free Full Text]
  13. Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 2002;3:509–19.[CrossRef][Medline]
  14. Zucker S, Pei DQ, Cao J, Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Cell Surface Proteases 2003;54:1–74.
  15. Pendas AM, Knauper V, Puente XS, et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 1997;272:4281–6.[Abstract/Free Full Text]
  16. Sedlacek R, Mauch S, Kolb B, et al. Matrix metalloproteinase MMP-19 (RASI 1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. Immunobiology 1998;198:408–23.[Medline]
  17. Yang MZ, Kurkinen M. Cloning and characterization of a novel matrix metalloproteinase (MMP), CMMP, from chicken embryo fibroblasts-CMMP, Xenopus XMMP, and human MMP19 have a conserved unique cysteine in the catalytic domain. J Biol Chem 1998;273:17893–900.[Abstract/Free Full Text]
  18. Mueller MS, Mauch S, Sedlacek R. Structure of the human MMP-19 gene. Gene 2000;252:27–37.[CrossRef][Medline]
  19. Stracke JO, Fosang AJ, Last K, et al. Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett 2000;478:52–6.[CrossRef][Medline]
  20. Stracke JO, Hutton M, Stewart M, et al. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19—evidence for a role as a potent basement membrane degrading enzyme. J Biol Chem 2000;275:14809–16.[Abstract/Free Full Text]
  21. Djonov V, Hogger K, Sedlacek R, Laissue J, Draeger A. MMP-19: cellular localization of a novel metalloproteinase within normal breast tissue and mammary gland tumours. J Pathol 2001;195:147–55.[CrossRef][Medline]
  22. Impola U, Toriseva M, Suomela S, et al. Matrix metalloproteinase-19 is expressed by proliferating epithelium but disappears with neoplastic dedifferentiation. Int J Cancer 2003;103:709–16.[CrossRef][Medline]
  23. Impola U, Jeskanen L, Ravanti L, et al. Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Br J Dermatol 2005;152:720–6.[CrossRef][Medline]
  24. Pendas AM, Folgueras AR, Llano E, et al. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol Cell Biol 2004;24:5304–13.[Abstract/Free Full Text]
  25. Kolb C, Mauch S, Krawinkel U, Sedlacek R. Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chronically, inflamed synovium. Exp Cell Res 1999;250:122–30.[CrossRef][Medline]
  26. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. J Cell Biol 2001;152:777–84.[Abstract/Free Full Text]
  27. Fusenig NE. Growth and differentiation characteristics of transformed keratinocytes from mouse and human skin in vitro and in vivo. In: Breitkreutz D, Dzarlieva RT, Boukamp P, Bohnert A, Tilgen W, editors. J Invest Dermatol 1983;81:168–75s.[CrossRef]
  28. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998;4:923–8.[CrossRef][Medline]
  29. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. J Cell Biol 2001;152:777–84.[Abstract/Free Full Text]
  30. Bajou K, Maillard C, Jost M, et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004;23:6986–90.[CrossRef][Medline]
  31. Kapur JN, Sahoo PK, Wong AKC. A new method for Gray-level picture thresholding using the entropy of the histogram. Comput Vis Graph Image Process 1985;29:273–85.
  32. Kohler R. A segmentation system based on thresholding. Comput Graph Image Process 1985;15:319–38.
  33. Passaniti A, Taylor RM, Pili R, et al. Methods in laboratory investigation—a simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement-membrane, heparin, and fibroblast growth-factor. Lab Invest 1992;67:519–28.[Medline]
  34. Mueller MM, Fusenig NE. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 2002;70:486–97.[CrossRef][Medline]
  35. Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839–49.[CrossRef][Medline]
  36. Hieta N, Impola U, Lopez-Otin C, Saarialho-Kere U, Kahari VM. Matrix metalloproteinase-19 expression in dermal wounds and by fibroblasts in culture. J Invest Dermatol 2003;121:997–1004.[CrossRef][Medline]
  37. Sadowski T, Dietrich S, Koschinsky F, et al. Matrix metalloproteinase 19 processes the laminin 5{gamma}2 chain and induces epithelial cell migration. Cell Mol Life Sci 2005;62:870–80.[CrossRef][Medline]
  38. Titz B, Dietrich S, Sadowski T, Beck C, Petersen A, Sedlacek R. Activity of MMP-19 inhibits capillary-like formation due to processing of nidogen-1. Cell Mol Life Sci 2004;61:1826–33.[Medline]
  39. Sadowski T, Dietrich S, Koschinsky F, Sedlacek R. Matrix metalloproteinase 19 regulates insulin-like growth factor-mediated proliferation, migration, and adhesion in human keratinocytes through proteolysis of insulin-like growth factor binding protein-3. Mol Biol Cell 2003;14:4569–80.[Abstract/Free Full Text]
  40. Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin {alpha}1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A 2000;97:2202–7.[Abstract/Free Full Text]
  41. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481–90.[CrossRef][Medline]
  42. Andarawewa KL, Boulay A, Masson W, et al. Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res 2003;63:5844–9.[Abstract/Free Full Text]
  43. Masson V, de la Ballina LR, Munaut C, et al. Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J 2005;19:234–6.[Abstract/Free Full Text]
  44. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737–44.[CrossRef][Medline]
  45. Chantrain CF, Shimada H, Jodele S, et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004;64:1675–86.[Abstract/Free Full Text]
  46. Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003;35:252–7.[CrossRef][Medline]
  47. McCawley LJ, Crawford HC, King LE, Mudget J, Matrisian LM. A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 2004;64:6965–72.[Abstract/Free Full Text]
  48. Rudolph-Owen LA, Chan R, Muller WJ, Matrisian LM. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res 1998;58:5500–6.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
V. W.M. van Hinsbergh and P. Koolwijk
Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead
Cardiovasc Res, May 1, 2008; 78(2): 203 - 212.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Gutierrez-Fernandez, A. Fueyo, A. R. Folgueras, C. Garabaya, C. J. Pennington, S. Pilgrim, D. R. Edwards, D. L. Holliday, J. L. Jones, P. N. Span, et al.
Matrix Metalloproteinase-8 Functions as a Metastasis Suppressor through Modulation of Tumor Cell Adhesion and Invasion
Cancer Res., April 15, 2008; 68(8): 2755 - 2763.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jost, M.
Right arrow Articles by Noël, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jost, M.
Right arrow Articles by Noël, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online